Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
2546 The University of Texas at San Antonio (144434)
Principal Investigator: Klose, Karl
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 15,581
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 5/13/23 - 12/31/23
Restricted Research: YES
Academic Discipline: none
Department, Center, School, or Institute: So Tx Ctr Emerg Infect Disease
Title of Contract, Award, or Gift: COVID 19 Vaccine Development
Name of Granting or Contracting Agency/Entity:
University of Texas Health Science Center San Antonio
CFDA: 0
Program Title: none
Note:
SAMs 1.1.1 and 1.1.4; The vaccine platform Fn-iglD, developed by Dr. Karl Klose at UTSA, exhibits high levels of safety and efficacy against pulmonary tularemia in three different animal models, including non-human primates (NHP). We will adapt this optimal LAV platform to express the SARSCOV2 spike protein (Fn iglD-S), and evaluate the antibodies induced in vaccinated animals to determine if they have neutralizing activity that could ameliorate COVID19 infection. The Klose laboratory at UTSA has an ongoing vaccine contract with Dr. Kenneth Carson at Southwest Research Institute, so this established collaboration will dramatically enhance this COVID19 research effort. Moreover, Dr. Klose has a scientific connection with Dr. Luis Martinez at Texas Biomedical Research Institute, and his expertise in evaluating immune correlates of vaccines against viral diseases, as well as facilities to work with live SARSCOV2 virus, will be a tremendous addition to this project. Results of this proof-of-concept study will facilitate the submission of more complex nonhuman primate studies using the most appropriate NHP model being evaluated at TBRI.
Discussion: No discussion notes